MetaCap

Turn Therapeutics Inc. (TTRX)

NASDAQ: TTRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.10-0.545 (-6.31%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TTRX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$247.49M
EPS (TTM)
-$0.43
52-week range
2.70 – 16.45
Day range
7.93 – 9.20
Volume / Avg
82.67K / 119.32K
Beta
—

52-week range

$2.70$16.45

TTRX stock today

On Nov 20, TTRX ended the session at $8.10, shedding $0.545 (6.31%), versus the S&P 500's 3.70% decline. At this level, TTRX sits in the middle of its 52-week range of $2.70 to $16.45: 50.8% below the high, set on Sep 18, 2026 and 199.8% above the low. TTRX is up 105.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 147.6%.

Turn Therapeutics has posted a net loss over the last twelve months (EPS of -$0.43), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Turn Therapeutics

Company profile

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Bradley E. Burnam
Headquarters
Westlake Village, CA
Employees
2

Financial highlights

Full financials

Turn Therapeutics reported a net loss of $3.2 million, compared with a loss of $1.8 million a year earlier. Diluted earnings per share came in at -$0.12.

Turn Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue——
Growth——
Net income$-3.19M$-1.77M
EPS (diluted)$-0.12$-0.07

Analyst forecast

Forecast

Consensus (2 analysts)

strong_buy

Avg. price target

$25.00+208.83%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $24.00High $26.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.21 vs —

TTRX news

All TTRX news

Turn Therapeutics peers

Health Care sector
TTRX peer companies
CompanyPrice% ChgMarket capCompare
QTTBQ32 Bio Inc.8.34-1.65%$249.57Mvs TTRX
LFCRLifecore Biomedical Inc.6.39+0.31%$242.22Mvs TTRX
CAMPCAMP4 Therapeutics Corporation3.79-5.25%$237.84Mvs TTRX
PRLDPrelude Therapeutics Incorporated3.23-0.77%$258.63Mvs TTRX
ALTAltimmune Inc.1.33-5.67%$258.80Mvs TTRX
EBSEmergent BioSolutions Inc.5.05-1.94%$259.65Mvs TTRX
VCREVicore Pharma Holding AB ADR9.41-5.09%$264.89Mvs TTRX
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs TTRX

Indexes, lists and sector

Turn Therapeutics stock FAQ

What is Turn Therapeutics's stock price today?

TTRX last traded at $8.10 as of Nov 20, 4:00 PM EST, down 6.31% on the day. Prices are delayed at least 15 minutes.

Who is Turn Therapeutics's CEO?

Mr. Bradley E. Burnam is the chief executive officer of Turn Therapeutics Inc., which has about 2 employees.

What is the TTRX 52-week high?

The 52-week high for TTRX is $16.45 and the 52-week low is $2.70. The stock is currently 50.8% below its high.

Compare TTRX